Please login to the form below

Not currently logged in
Email:
Password:

Lilly to run two Alzheimer's trials

Eli Lilly and Company is to begin enrolling patients in two trials investigating a potential treatment to delay the progression of Alzheimer's

Eli Lilly and Company is to begin enrolling patients in two phase III clinical trials investigating a potential treatment to delay the progression of mild to moderate Alzheimer's disease.

The identical, multi-centred, randomised, double-blind, placebo-controlled trials will enrol a total of 2,000 patients aged over 55, from over 16 countries. The trials, known as Expedition and Expedition 2, will examine solanezumab compared with a placebo over a treatment period of 18 months. Patients will be permitted to continue taking any treatments for the symptoms of the disease during their participation in the trials.

"Current therapies available to treat Alzheimer's disease may help with symptoms, but they haven't been proven to change the disease progression," said Dr Eric Siemers, medical director, Alzheimer's disease research for Eli Lilly and Company. "Biomarker results from a phase II solanezumab trial give us hope that Lilly is on a path towards a treatment that may slow the rate of progression of Alzheimer's disease."

The Expedition trial will be conducted in Argentina, Brazil, Canada, Japan, and United States. Expedition 2 will be conducted in Australia, France, Germany, Italy, Japan, Korea, Poland, Russia, Spain, Sweden, Taiwan, United Kingdom, and United States.

21st May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics